WEST BEND, Wis., Aug. 22, 2011 /PRNewswire/ — Clinigene
International Limited, an India-based Central and Bioanalytical
Laboratory and Phase I-IV Clinical Research Organization, and
Spaulding Clinical Research, LLC, US-based leading-edge Clinical
Pharmacology, Cardiac Core Lab, and Medical Device Manufacturer,
announce a strategic partnership agreement. This partnership
establishes a reliable, trustworthy, and cost-efficient global
footprint for clinical pharmacology services providing an
opportunity for both organizations to engage pharmaceutical clients
strategically and accelerate First-In-Human to Proof-of-Concept
clinical development.
“Pharmaceutical clients globally are increasingly seeking
strategies to expedite their early clinical development,
streamlining processes while maintaining high quality. Our
strategic partnership is designed to deliver this in a very
cost-effective manner,” states Dr. Abhijit Barve, Chief Operating
Officer of Clinigene. “The strengths of both companies are
very complementary with Clinigene providing the preclinical
development (through sister-company Syngene), Spaulding providing
FIH/SAD/MAD, and Clinigene providing DDI and efficient
Proof-of-Concept, supported by Clinigene’s Central and
Bioanalytical Laboratories. With Clinigene’s expertise and
cost-effective approach to BA/BE and Spaulding’s market-leading TQT
study and Cardiac Core Lab expertise, our clients are able to
easily structure a program for their compound that delivers
high-value while keeping the molecule knowledge experts involved
throughout the entire early clinical development of the compound,”
states Randol Spaulding, CEO of Spaulding Clinical.
Clinigene operates a CAP-accredited Central Laboratory and
GLP-compliant Bioanalytical Laboratory for small and large
molecules, both equipped with state-of-art technology, as well as a
94-bed clinical pharmacology unit in Bangalore, India which excels
at Bioavailability/Bioe
‘/>”/>
